These exosomes deliver anti-tumor molecules, such as tumor-suppressive miRNAs (e.g., miR-146a) or siRNAs targeting oncogenes like KRAS, effectively downregulating tumor-promoting pathways [39]. The gene discussed is KRAS; the disease is neoplasm.